| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8714392 | The Journal of Allergy and Clinical Immunology: In Practice | 2018 | 13 Pages |
Abstract
In this study, AR101 demonstrated an acceptable safety profile and demonstrated clinical activity as a potential immunomodulatory treatment option in peanut-allergic children over the age of 4, adolescents, and young adults.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
J. Andrew MD, Jonathan M. MD, PhD, Stacie M. MD, Rima MD, Amal H. MD, Julie MD, Stephanie A. MD, Susan S. MD, Edwin H. MD, Brian P. MD, Benjamin P. MD, PhD, Jennifer MD, Antonella MD, PhD, Andrew J. MD, PhD, Elena MD, A. Wesley MD,